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Introduction: The aim of this study was to characterize interleukin 17 (IL-17) and interleukin 22 (IL-22) producing
cells in peripheral blood (PB), skin, synovial fluid (SF) and synovial tissue (ST) in patients with psoriasis (Ps) and
psoriatic arthritis (PsA).
Methods: Flow cytometry was used to enumerate cells making IL-22 and IL-17, in skin and/or SF and PB from 11
patients with Ps and 12 patients with PsA; skin and PB of 15 healthy controls and SF from rheumatoid arthritis (RA)
patients were used as controls. Expression of the interleukin 23 receptor (IL-23R) and chemokine receptors CCR4
and CCR6 was examined. Secretion of IL-17 and IL-22 was measured by ELISA. ST was analysed by
immunohistochemical staining of IL-17 and IL-22.
Results: Increased frequencies of IL-17+ and IL-22+ CD4+ T cells were seen in PB of patients with PsA and Ps. IL-17
secretion was significantly elevated in both PsA and Ps, whilst IL-22 secretion was higher in PsA compared to Ps and
healthy controls. A higher proportion of the CD4+ cells making IL-17 or IL-22 expressed IL-23R and frequencies of
IL-17+, CCR6+ and CCR4+ T cells were elevated in patients with Ps and those with PsA. In patients with PsA, CCR6+
and IL-23R + T cells numbers were elevated in SF compared to PB. Increased frequencies of IL-17+ and IL-22+ CD4+ T
cells were demonstrated in Ps skin lesions. In contrast, whilst elevated frequencies of CD4+ IL-17+ cells were seen in
PsA SF compared to PB, frequencies of CD4+ IL-22+ T cells were lower. Whereas IL-17 expression was equivalent in
PsA, osteoarthritis (OA) and RA ST, IL-22 expression was higher in RA than either OA or PsA ST, in which IL-22 was
strikingly absent.
Conclusions: Elevated frequencies of IL-17 and IL-22 producing CD4+ T cells were a feature of both Ps and PsA.
However their differing distribution at disease sites, including lower frequencies of IL-22+ CD4+ T cells in SF compared
to skin and PB, and lack of IL-22 expression in ST suggests that Th17 and Th22 cells have common, as well as divergent
roles in the pathogenesis of Ps and PsA.Introduction
Psoriasis (Ps) is a common inflammatory disease of the
skin affecting 1% to 3% of the population [1-3]. It is com-
plicated in up to 30% of cases by psoriatic arthritis (PsA)
[4]. The arthritis takes various forms and is a member of
the spondyloarthropathies (SpAs) [5]. Ps alone produces
significant disability; when combined with PsA, the* Correspondence: h.benham@uq.edu.au
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reproduction in any medium, provided the orcondition can be especially debilitating, and treatment for
both skin and joints remains suboptimal.
Whereas recent evidence implicates interleukin 22 (IL-
22) in the pathogenesis of skin disease in Ps [6,7], PsA has
been postulated to more likely involve IL-17 [8,9]. Both cy-
tokines can be made by the T helper 17 (Th17) cell subset,
but recent reports have described T cells that make IL-22
alone [10,11]. These T cells, subsequently termed Th22
cells, produce IL-22 without IL-17 or interferon γ (IFNγ)
and are characterized by the expression of certain chemo-
kine receptors, including chemokine receptor 4 (CCR4)
and CCR6, which can influence homing to skin and joints
[12]. Both Th17 and Th22 cells are influenced by the cyto-
kine IL-23, which is required for their expansion andl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and PsA [14].
Despite increasing evidence of their involvement in Ps
and PsA, the relative roles of Th22 and Th17 cells in
these conditions are not known. In this study, we char-
acterized cells making IL-22 and/or IL-17 in skin, syn-
ovial fluid (SF), synovial tissue (ST) and peripheral blood
(PB) of Ps and PsA patients, together with PB and skin
from healthy controls and SF from rheumatoid arthritis
(RA) patients. We examined the expression of IL-23 re-
ceptor (IL-23R) and the chemokine receptors CCR4 and
CCR6, which influence traffic of these cells into skin and
joints. ST expression of IL-17 and IL-22 was analysed by
immunohistochemical staining.Methods
Patients
PB samples were obtained from 12 patients with Ps, 11 pa-
tients with PsA and 15 healthy controls. Skin biopsies
(4 mm) were obtained from seven patients with Ps and
healthy skin samples from seven patients undergoing plas-
tic surgical procedures. SF samples were collected from
seven patients with PsA and six patients with RA. All
patients with PsA fulfilled the Classification Criteria for
Psoriatic Arthritis criteria [15], and Ps patients were diag-
nosed by a consultant dermatologist. Demographics and
disease parameters were recorded (Table 1). The study was
approved by the Addenbrooke’s Hospital and Repatriation
General Hospital local ethics committee, and written in-
formed consent was given by all patients.Table 1 Baseline clinical and demographic characteristics of p
healthy donorsa
Patient characteristics Psoriatic arthritis (N =
Age, mean ± SD (years) 52 ± 17
Sex, F/M 6/5
Duration of arthritis, mean ± SD (years) 11 ± 2
Duration of psoriasis, mean ± SD (years) 18 ± 8
Current treatment Nil = 2
Steroids = 1
Methotrexate = 4
Sulphasalazine = 2
Azathioprine = 1
Etanercept = 1
Adalimumab = 1
Infliximab = 1
PASI score, mean ± SD 12 ± 6
Joint count, mean ± SD 5 ± 13
aNA, Not applicable; PASI, Psoriasis Area and Severity Index; PUVA, Psoralen and ultPreparation and stimulation of PBMCs and SFMCs
Peripheral blood mononuclear cells (PBMCs) and syn-
ovial fluid mononuclear cells (SFMCs) were purified
from PB and SF by centrifugation using a Ficoll-
Hypaque gradient (GE Healthcare Biosciences AB,
Uppsala, Sweden). PBMCs and SFMCs were adjusted to
a final concentration of 106/ml in RPMI 1640 medium
with 10% heat-inactivated foetal calf serum, 1% glutamine/
penicillin/streptomycin and 2% 2-[4-(2-hydroxyethyl)
piperazin-1-yl]ethanesulphonic acid (HEPES). For sur-
face phenotype and intracellular cytokine staining,
PBMCs and SFMCs were seeded into 24-well plates
(Nalge Nunc, Roskilde, Denmark) at 2 × 106 cells/well
and stimulated ex vivo with phorbol 12-myristate 13-
acetate (50 ng/ml; Calbiochem, Nottingham, UK) and cal-
cium ionomycin (1 μg/ml; Sigma-Aldrich, St Louis, MO,
USA) for five hours. GolgiStop protein transport inhibitor
(BD Biosciences, Mountain View, CA, USA) was added at
the beginning of the stimulation.
Cytokine secretion
PBMCs were seeded into 96-well culture plates (Nalge
Nunc) at 105/200 μl/well in triplicate and stimulated
with anti-CD3/CD28 beads (105 beads/well; Invitrogen,
Oslo, Norway). Following incubation for four days, cell-
free supernatants were collected and the concentrations
of IL-17 and IL-22 were assessed using enzyme-linked
immunosorbent assay kits according to the manufac-
turer’s instructions (eBioscience, San Diego, CA, USA).
The detection limits were 4 pg/ml for IL-17 and 8 pg/ml
for IL-22.soriatic arthritis patients, psoriasis patients and
11) Psoriasis (N = 12) Healthy donors (N = 15)
51 ± 19 43 ± 12
4/8 9/6
NA NA
25 ± 12 NA
Nil = 1 Nil
Topical steroids = 4
PUVA = 4
Methotrexate = 1
Acitretin = 2
Cyclosporine = 1
13 ± 7 0
NA 0
raviolet A light phototherapy.
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Dermal single-cell suspensions were obtained from skin
samples following overnight incubation in dispase and col-
lagenase 1 mg/ml at 4°C (both from Invitrogen, Paisley,
UK). Epidermis and dermis samples were separated, and
the dermis was cultured for 36 to 48 hours at 37°C in
RPMI 1640 medium supplemented with 5% pooled hu-
man serum (First Link, Birmingham, UK), 0.1% gentami-
cin reagent solution (Gibco, Grand Island, NY, USA) and
1% 1 mol/L HEPES buffer (Sigma-Aldrich, Irvine, UK).
Dermal single-cell suspensions were stimulated as de-
scribed for PBMCs and SFMCs.
Flow cytometry
Flow cytometry was used to analyse surface phenotype and
intracellular cytokine production by PBMCs, SFMCs and
skin-derived mononuclear cells. Cells were stained with
antibodies against surface antigens and intracellular cyto-
kines as previously described [16]. Live CD4+ T cells were
gated, and the percentages of these cells producing IL-17,
IFNγ and IL-22 were calculated. Skin cells were stained
with LIVE/DEAD® Fixable Near-IR Dead Cell Stain
Kit (Invitrogen, Oregon, USA) to exclude dead cells
from analysis. The FACSCanto II Flow Cytometry
System (BD Biosciences) and FlowJo software (Tree
Star, Ashland, OR, USA) were used for analysis. Anti-
bodies used were allophycocyanin-cyanine 7 (Cy7)-labelled
anti-CD3 (BioLegend, San Diego, CA, USA), phycoerythrin
(PE)-Cy7-labelled anti-CD4, PE-Cy5-labelled αβ T-cell
receptor (eBioscience), biotin-labelled anti-IL-23R (R&D
Systems, Minneapolis, MN, USA) used with Qdot
605 streptavidin conjugate (Invitrogen), PE-labelled
anti-CCR6 (BD Biosciences), peridinin-chlorophyll/
Cy5.5-labelled anti-CCR4 (BioLegend), fluorescein
isothiocyanate-labelled anti-IL-17, eFluor 450-labelled
anti-IFNγ (eBioscience) and Alexa Fluor 647-labelled anti-
IL-22 (Molecular Probes, Eugene, OR, USA). Appropri-
ately conjugated immunoglobulin G (IgG) antibodies were
used as isotype controls.
Synovial tissue
ST samples from RA, PsA and OA patients were obtained
at the time of knee arthroscopy or total knee replacement
surgery at the Rheumatology Unit of the Repatriation Gen-
eral Hospital, Daw Park, South Australia, Australia. ST
samples were snap-frozen in Tissue-Tek OCT compound
(Miles Laboratories, Elkhart, IN, USA) and stored at −80°C.
Cryostat sections (6 μm) were cut and mounted on adhe-
sive glass slides (Knittelglaser, Braunschweig, Germany).
Immunohistochemistry
Serial sections were stained with the following primary anti-
bodies: rabbit polyclonal anti-human IL-17Ab (Santa Cruz
Biotechnology, Santa Cruz, CA, USA), rabbit polyclonalanti-human IL-22Ab (Abcam, Cambridge, UK) and rabbit
polyclonal anti-human IL-23Ab (Abcam). We used 3 μg/ml
goat anti-rabbit IgG (P0448; Dako, Glostrup, Denmark) as
a secondary antibody and 7 μg/ml swine anti-goat IgG
(ACI3404; Invitrogen) or 13 μg/ml rabbit anti-swine IgG
(P0164; Dako) as tertiary antibody. We used a previously
described [17-19] three-step peroxidase-based immunohis-
tochemical staining technique for IL-22 and IL-23. For
staining of IL-17, biotinylated tyramine was used for amp-
lification with the tyramine signal amplification TSA
Biotin System kit (PerkinElmer, Waltham, MA, USA) as
previously described [20]. Controls were included in each
histochemical labelling run; negative control irrelevant/
isotype-matched immunoglobulins were applied to the sec-
tions instead of the primary antibody, or the primary anti-
body was omitted.
Semiquantitative scoring analysis of
immunohistochemistry results
After the slides were stained, the tissue sections were mea-
sured by two independent observers using semiquantitative
analysis. IL-17 and IL-22 staining was scored using a five-
point scale (0 to 4) scoring system as previously described
[21]. Assessment was carried out according to the percent-
age of positively stained cells as follows: 0 = no staining,
1 = <10%, 2 = 11% to 25%, 3 = 26% to 50% and 4 = >50%.
Statistical analysis
All data are presented as the mean ± SEM. An unpaired
Student’s t-test was used to detect differences between
the means of two normally distributed groups, and the
Mann–Whitney U test was applied for non–normally
distributed groups. One-way or two-way analysis of
variance with the Bonferroni multiple comparison post
hoc test was used to compare multiple means. Pearson’s
correlation coefficient was used to test the correlations.
Significance values shown on the figures are as follows:
*P < 0.05, **P < 0.01 and ***P < 0.001. All analyses were
performed using GraphPad Prism 5 software (GraphPad
Software, La Jolla, CA, USA).
Results
Frequency of IL-17+ and IL-22+CD4+ T cells are increased
in PBMCs of patients with both PsA and Ps
Using flow cytometry, we evaluated intracellular expression
of IL-17 and IL-22 and observed a higher proportion of IL-
17-producing cells within the PBMCs of PsA and Ps pa-
tients compared with that of healthy controls (1.0% and
1.1% vs. 0.57%, respectively; P < 0.05, P < 0.01, respectively)
(Figure 1A). The percentages of IL-22-positive CD4+ T
cells were also increased in PBMCs from patients with PsA
compared with those of healthy controls (0.95% vs. 0.51%;
P < 0.05), but the percentage increase in Ps patients rela-
tive to controls (0.81% vs. 0.51%; P > 0.05) was not
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Figure 1 Frequency of interleukin-17+ and interleukin-22+CD4+ T cells in the peripheral blood mononuclear cells of patients with psoriatic
arthritis patients with psoriasis and healthy controls. The frequency of interleukin 17 (IL-17)-positive CD4+ T cells (A) and IL-22-positive CD4+ T cells
(C) in patients with psoriasis (Ps) or psoriatic arthritis (PsA) and healthy controls. The percentages of total CD4+ T cells are shown. Typical examples of
intracellular staining of IL-17 (B) and IL-22 (D) are also shown after gating for CD3+CD4+ T cells. * p<0.05, **p<0.01, ***p<0.001 FSC = Forward Scatter.
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ences in the frequency of IL-17+ and IL-22+CD4+ T
cells between patients with Ps alone and those with
PsA (Figures 1A and 1C).
Increased secretion of IL-17 and IL-22 by PBMCs from
psoriatic arthritis and psoriasis patients
The concentrations of IL-17 in supernatants secreted by
stimulated PBMCs of PsA patients (1,287.74 ± 424.80
pg/ml) and Ps patients (1,513.12 ± 354.91 pg/ml) were
significantly higher than those from healthy controls
(538.60 ± 199.10 pg/ml; P < 0.05 and P < 0.05, respect-
ively) (Figure 2A). Concentrations of IL-22 secreted by
PBMCs of patients with PsA (234.20 ± 62.86 pg/ml), but
not those of patients with Ps (107.70 ± 33.96 pg/ml), were
significantly increased compared to healthy controls
(62.86 ± 19.90 pg/ml; P < 0.01 and P > 0.05, respectively)
(Figure 2B). Moreover, combining the data from all sub-
jects tested showed a positive correlation between the per-
centages of IL-17+CD4+ and IL-22+CD4+ T cells with the
amounts of IL-17 and IL-22 in culture supernatants
(r = 0.5929, P < 0.001; r = 0.4324, P < 0.01), respectively
(Figures 2C and 2D). However, the amount of IL-22secreted by PBMCs was significantly higher in PsA pa-
tients than in patients with only Ps (256.1 pg/ml vs. 120.8
pg/ml; P < 0.05), even though the frequency of IL-22+
cells in PBMCs did not differ significantly in the two
conditions.
Coexpression of cytokines by CD4+ T cells in PBMCs of
PsA and Ps and in healthy controls
Cells were analysed for coexpression of the cytokines IL-17,
IL-22 and IFNγ. This analysis showed that a proportion of
IL-17+CD4+ T cells also produce IL-22 and IFNγ in the Ps
and PsA patients and in healthy donors (IL-17+IFNγ+:
25.5% for PsA, 26.5% for Ps and 44.7% for healthy controls;
IL-17+IL-22+: 9.1% for PsA, 12.7% for Ps and 16.6% for
healthy controls) (Figure 3A). The same is true for IL-
22+CD4+ T cells with a proportion also producing IL-
17 and IFNγ (IL-22+IFNγ+: 23.1% for PsA, 36.1% for Ps
and 45.7% for healthy controls; IL-22+IL-17+: 12% for PsA,
28.4% for Ps and 17.9% for healthy controls) (Figure 3B).
Thus the proportions of cells making IL-17 without con-
comitant IFNγ or IL-22 and of cells making IL-22 without
IFNγ or IL-17 (Th22 cells) was higher in both PsA and Ps
patients compared to healthy donors.
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Figure 2 Secretion of interleukin 17 and interleukin 22 by peripheral blood mononuclear cells from psoriatic arthritis and psoriasis patients
and from healthy controls. The concentrations (Conc) of interleukin 17 (IL-17) (A) and IL-22 (B) in culture supernatants of peripheral blood mononuclear
cells from patients with psoriasis (Ps) and patients with psoriatic arthritis (PsA) and from healthy controls four days after stimulation with anti-CD3/CD28.
Correlations between percentages of IL-17+ and IL-22+CD4+ T cells and the concentrations of IL-17 (C) and IL-22 (D) in culture supernatants. * p<0.05,
**p<0.01, ***p<0.001.
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coexpressed IL-23R in PBMCs of psoriasis and psoriatic
arthritis patients
Very little difference in the proportion of CD4+ T cells
expressing IL-23R was observed in PBMCs from patients
with PsA or Ps or from healthy controls (22.20% vs.
17.34% vs. 17.26%, respectively; P > 0.05) (Figure 3C). In
all subjects, however, a much higher proportion of the
CD4+ cells making IL-17 or IL-22 expressed IL-23R (IL-
17+ cells: PsA 52.9%, Ps 46.6% and healthy controls
46.1%; IL-22+ cells: PsA 38.8%, Ps 39.6% and healthy
controls 31.5%) (Figures 3D and 3E).
Chemokine expression by IL-17+ and IL-22+ T cells
Because human Th17 cells have been reported to express
CCR6 and CCR4, we investigated their expression by IL-
17+ and IL-22+ cells. PsA patients had increased fre-
quency of both IL-17+CCR6+ and IL-17+CCR4+ T cells
in their PBMCs compared to healthy controls (0.87% vs.
0.41%, P < 0.01; 0.50% vs. 0.19%, P < 0.05). Although pa-
tients with Ps showed significantly increased frequency of
IL-17+CCR4+ cells compared to healthy controls (0.36%
vs. 0.19%; P < 0.05), their increase in IL-17+CCR6+ cells
was not significant (0.64% vs. 0.41%; P > 0.05) (Figures 3F
and 3G). Circulating numbers of CD4+IL-22+CCR6+ and
IL-22+CCR4+ were equivalent amongst the patients withPs or PsA and healthy controls (Figures 3H and 3I). The
proportion of CD4+IL-17+ T cells coexpressing CCR6 was
70.6% in all participants combined and 43.9% for CCR4.
For CD4+IL-22+, the proportions were lower, with CCR6
expression at 59.3% and CCR4 at 25.1% (Figures 3J
and 3K).
Increased frequency of IL-17+ and IL-22+CD4+ T cells in
psoriatic skin lesions
Increased expression of IL-17 and IL-22 mRNA has
been reported in psoriatic skin lesions [6,22]. Psoriatic
and normal skin were therefore investigated to identify
resident skin T cells capable of making these cytokines.
Elevated frequency of IL-17+ and IL-22+CD4+ T cells
were seen in Ps compared to healthy skin (11.5% vs.
3.1%, P < 0.05, and 5.9% vs. 2.3%, P < 0.05, respectively)
(Figures 4A and 4B). Coexpression of the cytokines was
also examined. In Ps skin compared to normal skin, not
only were the percentages of IL-17+ and IL-22+ T cells
increased, but there also was a much higher proportion
of IL-17+ cells which were also positive for IL-22
(Figures 4C and 4D). In addition, Th22 cells (IL-22-
producing cells which do not also produce IL-17 or
IFNγ) were markedly elevated in Ps skin compared to
healthy skin (2.98% vs. 0.83%; P < 0.01) (Figure 4E). A
higher frequency of T cells in psoriatic skin expressed
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Figure 3 Coexpression of cytokines and chemokines by CD4+ T cells in peripheral blood mononuclear cells of psoriatic arthritis
patients, psoriasis patients and healthy controls. Coexpression of interleukin 22 (IL-22) and interferon γ (IFNγ) by IL-17+CD4+ T cells (A).
Coexpression of IL-17 and IFNγ by IL-22+CD4+ T cells (B). Expression of IL-23 receptor (IL-23R) by CD4+ T cells (C) and the proportions of CD4+IL-17+
T cells (D) and CD4+IL-22+ T cells (E) coexpressing IL-23R. Expression of chemokine receptor 6 (CCR6) and CCR4 by IL-17+ T cells (F) and (G) and by
IL-22+ T cells (H) and (I) in psoriasis (Ps) patients and psoriatic arthritis (PsA) patients compared with healthy controls. Coexpression of CCR6 and CCR4
by CD4+IL-17+ T cells (J) and CD4+IL-22+ T cells (K). * p<0.05, **p<0.01, ***p<0.001.
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(Ps skin 28.6% vs. Ps PB 17.3%; P < 0.05) (Figure 4F).
Increased frequency of CD4+IL-17+ cells, but de-
creased frequency of CD4+IL-22+ T cells, in psoriatic
arthritis synovial fluid compared to peripheral blood.
No previous studies have characterized both Th17 and
Th22 cells in psoriatic joints. We found higher percent-
ages of CD4+IL-17+ T cells in PsA SFMCs compared with
the same patients’ PBMCs (1.92% vs. 1.04%; P < 0.05)
(Figure 5A), but, in contrast, the frequency of CD4+IL-22+T cells was lower in SFMCs compared to PBMCs (0.66%
vs. 0.95%; P < 0.05) (Figure 5B). No differences in percent-
ages of CD4+IL-17+ and IL-22+ T cells were seen within
PsA SFMCs as compared to RA SFMCs (1.9% vs. 1.3%,
P > 0.05, and 0.66% vs. 0.45%, P > 0.05) (Figures 5C and
5D). Expression of both CCR6 (Figure 5E) and IL-23R
(Figure 4F) was increased in the SF compared to the
PB of patients with PsA.
IL-22 expression is absent in PsA ST and more highly
expressed in RA ST.
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Figure 4 Frequency of IL-17+ and IL-22 + CD4+ in skin resident T cells of psoriatic skin lesions compared to healthy skin and
interleukin 23 receptor coexpression in skin, synovial fluid and peripheral blood of psoriasis and psoriatic arthritis patients. Frequency
of interleukin 17-positive (IL-17+) and IL-22+CD4+ in psoriatic skin lesions compared to healthy skin (A) and (B). Frequency of IL-17+IL-22+CD4+
T cells in psoriatic skin lesions compared to healthy skin (C). Representative fluorescence-activated cell sorting plots demonstrating CD4+ T-cell
expression of IL-22 and IL-17 in psoriatic versus healthy skin (D). Percentages of Th22 cells in psoriatic and healthy skin (E). Percentage of CD4+ T
cells coexpressing IL-23 receptor (IL-23R) in paired synovial fluid (Syn) and peripheral blood (PB) from psoriatic arthritis (PsA) patients and in skin
and PB of psoriasis (Ps) patients (F). * p<0.05, **p<0.01, ***p<0.001.
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positive staining for IL-17 in nine of eleven patients with
PsA and in nine of eleven RA patient ST samples. By semi-
quantitative analysis, we found a trend toward higher expres-
sion of IL-17 in RA than in PsA, but this difference was notstatistically significant (Figures 6A and 6B). In contrast, IL-22
expression was not expressed in any of 11 PsA ST samples,
but was expressed in seven of eleven of the RA ST samples.
By semiquantitative scoring, we found that IL-22 staining
was significantly increased in RA compared to PsA and OA
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Figure 5 Frequency of CD4+IL-17+ T cells and CD4+IL-22+ T cells and coexpression of chemokine receptor 6 in synovial fluid and peripheral
blood of psoriatic arthritis and rheumatoid arthritis patients. Frequency of CD4+IL-17+ T cells and CD4+IL-22+ T cells in psoriatic arthritis (PsA)
synovial fluid (SF) and peripheral blood (PB) (A) and (B) and of CD4+IL-17+ and CD4+IL-22+ T cells in PsA and rheumatoid arthritis (RA) SF (C) and (D).
Percentages of CD4+IL-17+ T-cell-expressing chemokine receptor 6 (CCR6) in PB and SF of patients with PsA (E). * p<0.05, **p<0.01, ***p<0.001.
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ST of patients with PsA, RA or OA (data not shown).
Discussion
T helper (Th) cells have a central role in effecting and
modulating human immune responses. Naïve CD4+ T
cells commit to various subsets of Th or regulatory T
cells according to the local cytokine environment and
the effects of antigen-presenting cells, particularly den-
dritic cells, with which they interact. One subset, termed
Th17 cells, was first shown to develop from naïve precur-
sors under the influence of transforming growth factor β
(TGF-β) and IL-6 ± IL-1 and to depend on IL-23 for ex-
pansion and survival. More recent work has shown that
human Th17 cells can be generated by IL-6+IL-23+IL-1β
in the absence of TGF-β [23].
Th17 cells produce cytokines other than IL-17 and
were originally thought to be the main source of IL-22.
More recent data, however, show that some CD4+ T
cells make IL-22 alone, without IL-17; these cells havesubsequently been termed Th22 cells and are also
influenced by IL-23 [10,11]. IL-23, as well as its effects on
the production of other cytokines, is of particular signifi-
cance in relation to both Ps and PsA because genomewide
association studies have demonstrated that Ps is associated
with polymorphisms in genes encoding both IL-23 sub-
units (p40 and p19) and the IL23R gene; the latter is also
implicated in PsA and other forms of spondyloarthropathy
[24,25]. IL-23 p40 and p19 are overexpressed in Ps skin,
and it has been shown that a hypofunctional variant of IL-
23R is protective in psoriasis [26]. In addition to these
genetic associations, there are now substantial data impli-
cating the Th17–Th22–IL-23 axis in mouse models of
both Ps and SpA [7,16,25,27-31].
IL-17- and IL-22-producing T cells have been demon-
strated at various tissue sites in both PsA and Ps
[8,9,32-34], but the relative contribution of Th17 and
Th22 cells to each disease remains unclear. Therefore, in
our present study, we sought to enumerate cells making
IL-22 and/or IL-17 in skin, joint fluid and PB of Ps and
Figure 6 Representative interleukin 17 and interleukin 22 expression patterns in synovial tissue from osteoarthritis, rheumatoid arthritis and
psoriatic arthritis patients. (A) Positive cells show red staining; original magnification, ×200. (B) and (C) Semiquantitative (SQ) analysis shows grading of
the percentage of cells present in entire tissue: 0 = no staining, 1 = <10%, 2 = 10% to 25%, 3 = 25% to 50% and 4 = >50% for both (B) interleukin 17-
positive (IL-17+) and (C) IL-22+ in tissue samples from patients with osteoarthritis (OA), rheumatoid arthritis (RA) and psoriatic arthritis (PsA). * p<0.05,
**p<0.01, ***p<0.001.
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expression of IL-23R and chemokine receptors CCR4 and
CCR6, which influence trafficking of these cells into skin
and joints. We also pursued the expression of both IL-17
and IL-22 in synovial tissue.
We demonstrated significantly increased percentages of
IL-17+CD4+ T cells in the PB of PsA and Ps patients com-
pared to healthy controls, together with increased percent-
ages of IL-22+CD4+ T cells in PsA patients. In Ps, the
percentage of IL-22+ cells was increased, but not signifi-
cantly. Likewise, increased concentrations of IL-17 were
seen in supernatants of stimulated PBMCs in both PsA
and Ps, whereas increased IL-22 was seen significantly only
in PsA. There were positive correlations between IL-17
and IL-22 production and the frequency of IL-17+CD4+
and IL-22+CD4+ cells identified by intracellular staining,
suggesting that CD4+ T cells are the principal source of
IL-17 and IL-22 in the PB of both groups. These results
are in general agreement with the findings of previous
studies of IL-17 in PsA and Ps [8,9], but our failure to
demonstrate an increased percentage of IL-22+ cells or
production of IL-22 by Ps PBMCs was unexpected and
has not been previously reported. One possibility is that
IL-22-producing cells may be depleted from PB by recruit-
ment to skin lesions, although in our study there was no
significant difference in skin involvement as judged by
Psoriasis Area and Severity Index score in Ps patients
compared with PsA patients. Nevertheless, full matching
of patients for extent and activity of psoriasis may not
have been achieved.In line with the hypothesis that increased production of
or responsiveness to IL-23 drives increased numbers of IL-
17- and IL-22-producing cells in Ps and PsA, a higher pro-
portion of IL-17+CD4+ and IL-22+CD4+ cells expressed
IL-23R. There were also significant correlations between
numbers of IL-23R+ positive cells and numbers of CD4+ T
cells secreting IL-17 or IL-22 (data not shown). Th17 and
Th22 cells have previously been reported to express CCR6
and CCR4 [33,35], and, as expected, patients with PsA had
increased proportions of both IL-17+CCR6+ and IL-17+
CCR4+ cells in PB. Again, a difference was seen in Ps,
where we observed increased proportions of IL-17+ CCR4+
T cells, but not IL-17+CCR6+ T cells. The explanation for
this difference is unclear, but it might relate to differential
recruitment to skin and joints. Although the CCR6 ligand
CCL20 has been shown to be elevated and to recruit Th17
cells into inflamed joints [36,37], migration into the skin is
influenced by additional factors, including ligands for
cutaneous lymphocyte-associated antigen and integrins,
neither of which was examined in this study.
Examination of cells in skin and SF also produced
evidence of expansion of IL-23-driven T-cell subsets. In
Ps skin, there were increased percentages of IL-17+ and IL-
22+ cells compared to normal skin. Normal skin contained
many fewer CD4+ T cells, so the numbers of IL-17+ and
IL-22+ cells were very substantially increased, and, even in
comparison with Ps PB, the percentages of both IL-17+
and IL-22+ cells were increased approximately tenfold. Im-
portantly, cells producing IL-17 and IL-22 were shown
to comprise three subsets: a minority producing both
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the other. This finding emphasises the multiplicity of func-
tional subsets with the skin. It also was reflected in PB and
confirms and extends previously published data [38,39].
The proportion of IL-23R+CD4+ cells in the skin was also
increased compared to PB.
In a mouse model of Ps, plaques can be induced by
local IL-23 injection, and this is IL-22-dependent [28].
Therefore, the increased proportion of cells making IL-22
alone (that is, without IL-17 or IFNγ) in Ps skin compared
to joints was of particular interest, given that this has not
previously been studied in patients with both skin and
joint disease [10]. This preponderance of Th22 cells in
skin was in marked contrast to the findings in SF, where
they were not elevated. IL-22-producing cells, though in-
creased in PsA PB and expressing CCR6, might not be
recruited to the joint, perhaps because of a dominant ef-
fect of skin-specific homing receptors. It has previously
been reported that T cells in PsA SF lack expression of
CLA, which is seen on skin T cells in Ps [40].
Further to the SF findings, immunohistochemical staining
of ST from PsA and RA patients revealed that IL-22 expres-
sion was absent in all PsA samples but present in more
than 60% of the RA samples. IL-22 expression has previ-
ously been demonstrated in the synovium of RA patients
[41] and has been linked to the upregulation of receptor ac-
tivator of nuclear factor κB ligand expression in RA syn-
ovial fibroblasts and the induction of osteoclastogenesis
[42]. IL-22 expression has not been studied in PsA; how-
ever, recent work in a mouse model of SpA indicates that
IL-22 may act through Stat-3, mediating osteoblastic bone
remodelling, specifically at the entheseal site. Because this
IL-22 expression was found even in the absence of synovitis
in the mouse model [43], and since we observed a striking
and specific lack of IL-22 staining in PsA ST, it will be of
interest in future studies to determine whether IL-22 is also
expressed in entheseal biopsies from patients with PsA.
Conversely, IL-17+ cells were clearly elevated in SF from
PsA patients, and this has been noted in other forms of
spondyloarthritis and in RA [9,29,30]. Weak and equiva-
lent expression of IL-17 was demonstrated in both PsA
and RA patients. This is in keeping with the findings of
previous studies demonstrating that IL-17 expression is
not restricted to RA but is also observed in PsA [44,45].
Conclusion
Overall, the results of our present study strengthen the
case for the central involvement of the Th17–Th22–IL-
23 axis in both Ps and PsA. Th17 and Th22 cells may
have common as well as divergent roles in the pathogen-
esis of skin and joint disease in patients with Ps and
PsA, which has implications for potential treatment
strategies aimed at targeting Th17 and Th22 cells or
their generation.Abbreviations
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